Abstract
Fluoroquinolones (FQ) are an important family of synthetic antimicrobial agents being clinically used over the past thirty years. Currently some FQ are under investigation for the treatment of multidrug-resistant tuberculosis (MDRTB), defined as resistance to at least isoniazid and rifampicin, and are under investigation as first-line drugs. Their main biological target in Mycobacterium tuberculosis is the DNA gyrase, a topoisomerase II encoded by gyrA and gyrB that is essential to maintain the DNA supercoil. It has been demonstrated that mutations in short regions of DNA gyrase are associated with quinolone resistance or hypersusceptibility and take place in several MDR clinical isolates of M. tuberculosis. In this article we update§ our previous review (Carta et al. Anti-infective agents, 2008, 7, 134-147) about the anti mycobacterial properties, mode of action and structure activity relationship (SAR) studies of the known quinolone derivatives. Furthermore, we update the synthesis and activity of 3,9-disubstituted-6-oxo-6,9-dihydro-3H-[1,2,3]-triazolo[4,5-h,g]quinolonecarboxylic acids and their esters as a new class of potent and selective anti-mycobacterial agents, coupled with absence of cytotoxicity. Furthermore, particularly interesting is their activity against MDR M. tuberculosis.
Keywords: Anti-mycobacterial activity, DNA gyrase inhibitors, MDR-TB, quinolones, SAR analysis, triazoloquinolones antitubercular activity.
Anti-Infective Agents
Title:SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update
Volume: 11 Issue: 1
Author(s): Irene Briguglio, Sandra Piras, Paola Corona, Maria A. Pirisi, Daniela Jabes and Antonio Carta
Affiliation:
Keywords: Anti-mycobacterial activity, DNA gyrase inhibitors, MDR-TB, quinolones, SAR analysis, triazoloquinolones antitubercular activity.
Abstract: Fluoroquinolones (FQ) are an important family of synthetic antimicrobial agents being clinically used over the past thirty years. Currently some FQ are under investigation for the treatment of multidrug-resistant tuberculosis (MDRTB), defined as resistance to at least isoniazid and rifampicin, and are under investigation as first-line drugs. Their main biological target in Mycobacterium tuberculosis is the DNA gyrase, a topoisomerase II encoded by gyrA and gyrB that is essential to maintain the DNA supercoil. It has been demonstrated that mutations in short regions of DNA gyrase are associated with quinolone resistance or hypersusceptibility and take place in several MDR clinical isolates of M. tuberculosis. In this article we update§ our previous review (Carta et al. Anti-infective agents, 2008, 7, 134-147) about the anti mycobacterial properties, mode of action and structure activity relationship (SAR) studies of the known quinolone derivatives. Furthermore, we update the synthesis and activity of 3,9-disubstituted-6-oxo-6,9-dihydro-3H-[1,2,3]-triazolo[4,5-h,g]quinolonecarboxylic acids and their esters as a new class of potent and selective anti-mycobacterial agents, coupled with absence of cytotoxicity. Furthermore, particularly interesting is their activity against MDR M. tuberculosis.
Export Options
About this article
Cite this article as:
Briguglio Irene, Piras Sandra, Corona Paola, A. Pirisi Maria, Jabes Daniela and Carta Antonio, SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update, Anti-Infective Agents 2013; 11 (1) . https://dx.doi.org/10.2174/22113626130109
DOI https://dx.doi.org/10.2174/22113626130109 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Comparative Proteome Analysis of <i>Mycobacterium Tuberculosis</i> Strains - H37Ra, H37Rv, CCDC5180, and CAS/NITR204: A Step Forward to Identify Novel Drug Targets
Letters in Drug Design & Discovery The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Human Arylamine N-Acetyltransferase 1: A Drug-Metabolizing Enzyme and a Drug Target?
Current Drug Targets A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review
Cardiovascular & Hematological Disorders-Drug Targets Foreword
Current Topics in Medicinal Chemistry Mathematical Descriptors for the Prediction of Property, Bioactivity, and Toxicity of Chemicals from their Structure: A Chemical-Cum-Biochemical Approach
Current Computer-Aided Drug Design Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews Bacterial Resistance: Antibiotics of Last Generation used in Clinical Practice and the Arise of Natural Products as New Therapeutic Alternatives
Current Pharmaceutical Design Patent Selections
Recent Patents on Drug Delivery & Formulation Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design Preface
Current Drug Targets Antitubercular Properties of Substituted Hydroxycyclohexadienones
Letters in Drug Design & Discovery Editorial: Comparison of Forgotten Surgical Techniques for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Properties and Potency of Small Molecule Agents for Treatment of Mycobacterium Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)